Authors
Latest:
Using the Angiogenesis Inhibitor Pazopanib to Treat Ovarian CancerCarol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Latest:
The Role of Oncology Nurse Navigators in Healthcare ReformCarol Bush, BS, RN, discusses the role of oncology nurse navigators in healthcare reform.
Latest:
OS Results of a Study Evaluating Dabrafenib and Trametinib in MelanomaCaroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussy in Paris, discusses overall survival (OS) results of a recent study evaluating dabrafenib and trametinib in melanoma.
Latest:
Olaparib/Cediranib Combo Misses the Mark in Ovarian CancerOlaparib plus cediranib did not improve survival compared with chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.
Latest:
The Diagnosis of Thyroid CancerCarrie C. Lubitz, MD, MPH, assistant professor, Massachusetts General Hospital, discusses the diagnosis of thyroid cancer.
Latest:
Effects of Para-aortic Lymph Node Metastases on Endometrial Cancer SurvivalCarrie L. Langstraat, MD, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Latest:
Interesting Research in the Endometrial Cancer SpaceCasey M. Cosgrove, MD, discusses research exploring precision medicine concepts for endometrial cancer treatment.
Latest:
Pregnancy Disproved as Potential Trigger for Relapse in Hodgkin Lymphoma SurvivorsResearchers discovered that pregnancy while in remission of Hodgkin lymphoma does not increase the risk of cancer relapse, making this report the first largest study to specifically examine the impacts of pregnancy as a potential trigger for relapse in Hodgkin lymphoma survivors.
Latest:
T Cell Resistance to TGF-Beta in LymphomaCatherine Bollard, MBChB, MD, from the Baylor College of Medicine, discusses T cells and TGF-beta in Hodgkin's lymphoma and Non-Hodgkin lymphoma.
Latest:
Questions on Genetic Counseling in the Community SettingCatherine Fine, MS, Certified Genetic Counselor, lead, Clinical Cancer Services at Genome Medical, discusses questions on genetic counseling in the community setting.
Latest:
Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular LymphomaCatherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).
Latest:
Clinical Trials Exploring Bevacizumab in NSCLCCatherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.
Latest:
Biomarker Testing for Anal CancerCathy Eng, MD, discusses what can be done in order to integrate biomarker testing for anal cancer into clinical practice.
Latest:
Ongoing Clinical Trials in BRAF-Mutant CRCCathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the <em>BRAF</em>-mutant colorectal cancer patient population.
Latest:
A Study Examining Breast Cancer Mortality Rates Across 47 CountriesCecile Pizot, a biostatistician in Epidemiology at the International Prevention Research Institute, discusses a study that examined breast cancer mortality rates across 47 countries.
Latest:
Using Immunotherapy for the Treatment of MelanomaCeleste Lebbé, MD, from the Hôpital Saint Louis, in Paris, France, discusses the use of immunotherapy for the treatment of melanoma.
Latest:
MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLCTwo presentations at this year’s American Association for Cancer Research (AACR) annual meeting linked a specific microRNA (miRNA), miR-34a, to an active area in immunotherapy, programed cell death-1 (PD-1) protein and its ligand, PD-L1.
Latest:
Hypogammaglobulinemia and Abiraterone Therapy for Metastatic Prostate CancerDescription of 3 cases whereby significant septic complications occurred in the setting of abiraterone use that were associated with hypogammaglobulinemia.
Latest:
Dr. Chandra P. Belani on the Importance of Immunotherapies in Treating Lung CancerChandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, talks about how immunotherapies targeting PD-L1 and PD-1 are showing activity in lung cancer.
Latest:
Clinical Outcomes and Quality of Life in Ovarian CancerCharles A. (Trey) Leath III, MD, associate professor, gynecologic oncology, University of Alabama Birmingham Cancer Center, discusses a study that examined clinical outcomes and quality of life in ovarian cancer.
Latest:
Exploring Celecoxib for the Treatment of Breast CancerCharles Coombes, MD, professor of medical oncology, Imperial College London, discusses a study of celecoxib versus placebo in primary breast cancer patients.
Latest:
Geyer on Managing Toxicities of Olaparib in BRCA+/HER2- Breast CancerCharles Geyer, MD, advises his peers on how to manage the grade 3 or higher toxicities and any serious adverse events seen in the clinical trial setting with adjuvant olaparib.
Latest:
Investigating Immunotherapy Treatment in Renal Cell CarcinomaCharles G. Drake, MD, PhD, director of Genitourinary Oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting.
Latest:
Use of ARN-509 in Prostate CancerCharles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.
Latest:
The Results of the IBIS II TrialCharles L. Shapiro, MD, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.
Latest:
Dr. Charles M. Perou on the Evolution of Precision Medicine in Breast Cancer​Charles M. Perou, PhD, professor of Genetics, Pathology & Laboratory Medicine, Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses precision medicine in breast cancer and currently known biomarkers.
